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Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and
improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase
(PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most well-known
mechanisms of homologous recombination deficiency. However, other mechanisms, such as germline and
somatic mutations in other homologous recombination genes and epigenetic modifications, have also been
implicated in homologous recombination deficiency. The epidemiology and implications of these other mech-
anisms need to be better understood to improve the treatment strategies for these patients. Furthermore, an
evaluation of various diagnostic tests to investigate homologous recombination deficiency is essential. Compre-
hension of the role of homologous recombination deficiency in ovarian cancer also allows the development of
therapeutic combinations that can improve the efficacy of treatment. In this review, we discuss the epidemio-
logy and management of homologous recombination deficiency in ovarian cancer patients.
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’ INTRODUCTION
In ovarian cancer, patients harboring BRCA 1/2 mutations
exhibit different patterns of clinical behavior and respond
to treatment differently. The BRCA gene plays a role in
repairing DNA repair via homologous recombination (HR),
and mutation of this gene leads to HR deficiency (HRD).
HRD can also occur due to other mechanisms, such as ger-
mline mutations, somatic mutations and epigenetic modifi-
cations of other genes involved in the HR pathway. Ovarian
cancers with these alterations behave similarly to those with
BRCA mutations, and this behavior is termed the ‘‘BRCA-
ness’’ phenotype.
Using poly (ADP-ribose) polymerase (PARP) inhibitors in
patients with HRD compromises two pathways of DNA
repair, resulting in synthetic lethality. Recent studies have
confirmed that the efficacy of PARP inhibitors is improved
not only in ovarian cancers displaying germline or somatic
BRCA mutations but also in cancers in which HRD is caused
by other underlying etiologies.
In this review, we discuss how to evaluate HRD as well as
the epidemiology and management of HRD in ovarian cancer.
Homologous recombination deficiency and
PARP inhibitors
DNA breaks are repaired via different mechanisms to
protect the genome. For example, double-stranded breaks
are repaired by HR and non-homologous end joining
(NHEJ) (1). HR is more efficient at maintaining genomic
stability because it uses a homologous template, whereas
NHEJ is error-prone.
Unrepaired DNA damage can result in accumulated muta-
tions and unregulated cell division, and HRD is thus related
to cancer susceptibility (2,3). Moreover, large amounts of
DNA damage can lead to cell apoptosis. However, when
only HR is deficient, the activities of other DNA repair
mechanisms can prohibit the accumulation of excessive DNA
damage and apoptosis (2).
Base excision repair (BER) serves as another DNA repair
mechanism that acts on single-stranded breaks, and mem-
bers of the PARP protein family play essential roles in the
BER mechanism. PARPs bind to single-stranded break sites
and initiate the repair process, and these proteins are targe-
ted in oncology via the use of PARP inhibitors.
As mentioned previously, HRD by itself does not
always induce cellular apoptosis. However, when PARP
inhibitors are used in HRD cells, impairment of these
two DNA repair mechanisms together results in synthetic
lethality. In other words, mutations occurring in one of
two genes separately do not result in apoptosis, but the
impairment of both genes simultaneously leads to cell
death (synthetic lethality). In this situation, the accumu-
lation of DNA damage might be sufficient to induce
cell death (apoptosis), and clinical trials showing the
benefits of PARP inhibitors in HRD cancers support this
concept (4,5).DOI: 10.6061/clinics/2018/e450s
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Mechanisms implicated in homologous
recombination deficiency
The most described etiology of HRD is the mutation of
genes involved in HR repair. Mutations can occur in ger-
mline cells, which represent individual characteristics, or
somatic cells, which is a trait of tumor cells.
Germline BRCA 1 and BRCA 2 mutations are the most
well-known HRD etiology. Germline mutations are impor-
tant not only for treatment decisions but also for the evalua-
tion of cancer susceptibility and prevention strategies for
the patients and their relatives. BRCA 1/2 are involved in
hereditary breast and ovarian cancer syndrome, and numer-
ous trials evaluating PARP inhibitors have been performed
on patients presenting germline BRCA 1/2 mutations (5–8).
Patients without BRCA 1/2 mutations presented similar cli-
nical behaviors and responses to PARP inhibitors (4,9), and
these patients define the ‘‘BRCAness’’ phenotype (10,11). The
mechanisms underlying BRCAness are varied and include
somatic BRCA 1/2 mutations and germline or somatic muta-
tions in other genes related to HR repair.
Another possible etiology of HRD is the epigenetic modi-
fication of HR genes, such as methylation of the BRCA 1
promoter. Gene expression signatures present in germline
BRCA1 mutations were also observed in BRCA1-methylated
cancers (12). However, the implication of epigenetic mod-
ifications in HRD remain controversial. While Cunningham
et al. reported a survival advantage in patients with BRCA 1
promoter hypermethylation compared with BRCAwild-type
patients (13), other researchers found no survival advantage
(14,15) or worse survival for patients with the methylated
phenotype (16).
How to evaluate homologous
recombination deficiency
HRD can be tested using three main strategies:
 Germline mutation screening of genes related to HR
repair;
 somatic mutation screening of genes related to HR repair;
and
 evaluation of a genomic scar, which represents the geno-
mic instability secondary to HRD. An HRD score can be
calculated based on the loss of heterozygosity (LOH),
telomeric allelic imbalance, and large-scale transitions.
Germline mutation screening can be performed using next
generation sequencing (NGS) analysis of DNA from blood,
which has the advantage of being easy to obtain. Moreover,
the identification of a germline mutation allows the possibility
of genetic counseling.
Somatic mutation screening, on the other hand, is perfo-
rmed on DNA from tumor samples. This analysis can eval-
uate any mutation (germline and/or somatic) in HR genes
and is thus a broader evaluation, which is helpful for defining
treatment strategies, such as the use of PARP inhibitors. How-
ever, when a mutation is identified with this strategy, germline
analysis of normal cells is still necessary to determine whether
the mutation is germline or somatic (present in only the tumor)
(17). Limitations of somatic screening include the variability of
tumor samples available and intratumoral heterogeneity, which
potentially compromises the representativeness of the sample.
Finally, HRD can be assessed in a more functional way.
When HRD is present, genomic alterations accumulate, and
allelic imbalances can result in a ‘‘genomic scar’’, allowing
the investigation of HRD regardless of the underlying genetic
or epigenetic mechanism responsible. A high LOH (X14-16%),
for example, suggests the presence HRD. In the ARIEL2 trial,
which evaluated rucaparib in platinum-sensitive recurrent
ovarian cancer, LOH-high was defined by NGS using a cutoff
of 14%. The results showed that patients with BRCA 1/2 wild-
type and LOH-high benefited from rucaparib (9). LOH can
also be evaluated together with telomeric allelic imbalance and
large-scale transitions to generate an HRD score (MyChoices
HRD test, Myriad Genetics Inc., Salt Lake City, Utah).
Patients determined to have HRD (defined as any tumor that
scored X42 on the MyChoices HRD test) benefited from
maintenance niraparib in the NOVA trial (4).
Despite the ability of NGS to assess many genes during
germline or somatic mutation screening, the implications of
some mutations remain unknown. Moreover, NGS cannot
evaluate HRD due to other etiologies, such as epigenetic
modifications. Thus, functional evaluations of HRD can help
overcome these limitations.
In conclusion, each of these tests have different properties
and can be used in a complementary manner.
Epidemiology of HRD in ovarian cancer
Approximately 41-50% of ovarian carcinomas are esti-
mated to exhibit HRD (17,18). However, the frequency
of HRD varies according to the method utilized for its
evaluation (germline mutations, somatic mutations or HRD
score) and histological subtype. Table 1 shows the frequen-
cies of HRD in different studies according to the histolo-
gical subtype.
Pennington et al. (19) found HR gene germline mutations
in 24% of patients with epithelial ovarian cancer and soma-
tic mutations in 9% of these patients. Elvin et al. (18) eval-
uated the presence of BRCA mutations or LOH in different
histological subtypes. The serous subtype was associated
with a higher prevalence of HRD, with 43.8% of the patients
presenting BRCA mutations (BRCAmut, 18.7%) or BRCA
wild-type/LOH-high (BRCAwt/LOH-high, 25.1%). Other
epithelial ovarian carcinomas also exhibited elevated propor-
tions of HRD which occurred in 37.6% of endometrioid (12.6%
BRCAmut and 25% BRCAwt/LOH-H), 23.5% of carcino-
sarcoma (8.2% BRCAmut and 15.3% BRCAwt/LOHH)
and 12.6% of clear cell histologies (4.7% BRCAmut and 8.9%
BRCAwt/LOHH). The mucinous subtype, however, exhib-
ited no BRCA mutations, and only 8.1% of the patients
presented with BRCAwt/LOH-H. Upon specifically eval-
uating the presence of somatic mutations, Aghajanian et al.
Table 1 - Frequency of homologous recombination deficiency
according to the histological subtype.
Method Elvin et al.
(N=4114) (18)
Norquist et al.
(N=1915) (21)
Pennington et al.
(N=367) (19)
BRCA +
LOH-H
HR gene
mutations
HR gene
mutations
Serous 43.8% 27% 31%
Endometrioid 37.6% 23.8% 27%
Carcinosarcoma 23.5% - 33%
Clear Cell 13.6% 21.4% 26%
Epithelial NOS 47.7% - -
Mucinous 8.1% 28.6% 0%
LOH-H: Loss of heterozygosity; HR: homologous recombination; NOS: not
otherwise specified.
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found similar prevalences of somatic mutations in high-grade
serous ovarian carcinoma (HGSOC) and other histologies
(16% vs 18%, respectively, p=0.07). Once again, no somatic
mutations in HR genes were observed in mucinous ovarian
cancer.
In relation to high-grade versus low-grade serous carci-
noma, Norquist et al. (21) found a significant difference in the
germline and somatic mutation rates of HR genes, which
were 10.9% for low-grade versus 27% for HGSOC (odds ratio
(OR), 0.33; 95% confidence interval (CI), 0.1-0.8; p=0.02).
Regarding the specific genes compromised, in an evalua-
tion of HR gene mutations in ovarian cancer patients who
participated in the GOG 218 and GOG 262 trials, Norquist
et al. (21) showed germline or somatic mutations in BRCA1
gene in 12.3% of the cases, in BRCA2 gene in 6.5% and in
other non-BRCA HR genes in 6.8%. Elvin et al. (18) reported
similar results, with mutations in BRCA 1 gene in 11.6% of the
cases and BRCA 2 gene in 5.7%.
BRCA mutations occur more frequently in HGSOC, with
20% of these patients presenting germline or somatic muta-
tions in BRCA 1 or BRCA 2 (21). However, in the Norquist
et al. study (21), other histologies also presented consider-
able rates of BRCA 1 or 2 mutations (approximately 9% for
endometrioid ovarian cancer, 11% for clear cell ovarian cancer
and 8% for low-grade serous ovarian cancer). Alsop et al. (22)
exclusively evaluated the frequencies of germline BRCA 1 and
BRCA 2 mutations, finding mutations in 17% of patients
with HGSOC, 8.4% of patients with the endometrioid
histology and 6.3% of patients with the clear cell histology.
Somatic BRCA 1 and BRCA 2 mutations occur less often, with
prevalences of 2-5% and 2-3%, respectively (14,19).
The frequency of changes (mutation, deletion or amplifica-
tion) in each non-BRCA HR gene is much lower and more
heterogeneous. Table 2 lists the genes implicated in HR repair
and the frequencies of germline mutations reported in dif-
ferent studies. Table 3 describes the frequencies of somatic
gene changes. NGS was utilized in all the studies described in
the tables. Blood samples were utilized in trials that evaluated
germline mutations, and tumor samples were utilized in trials
evaluating somatic gene mutations.
Treatment of ovarian cancer with HRD
HRD carcinomas exhibit an increased responsiveness to
cytotoxic chemotherapy, especially platinum agents, in diffe-
rent treatment lines (19,23-25). Platinum agents act via directly
damaging DNA, and when HRD is present, the reduction of
DNA repair increases the accumulation of DNA damage,
leading to apoptosis. Pennington et al. showed that somatic
BRCA 1/2 mutations and mutations in other HR genes predict
platinum responsiveness and positively impact overall survi-
val, similar to germline BRCA 1/2 mutations (19).
Regarding PARP inhibitors, their benefit in HRD was first
shown in patients with BRCA 1/2 mutations. In a phase I
trial, the activity of olaparib was evaluated in heavily pre-
treated patients (mainly ovarian and breast cancer patients)
(26). Twelve of the 23 patients harboring BRCA mutations
presented a response or stable disease for at least 4 months,
Table 2 - Frequency of germline mutations in ovarian carcinoma.
(N) TCGA (14)
(316)
Pennington et al. (19)
(390)
Cunningham et al. (13)
(899)
Harter et al. (49)
(522)
Norquist et al. (50)
(1915)
Yates et al. (51)
(299)
BRCA1 8.5% 13.4% 3.5% 15.3% 9.5% 9%
BRCA2 6.3% 4.6% 3% 5.6% 5.1% 5.4%
EMSY
PTEN 0%
RAD51C 0.7% 3% 2.5% 0.6% 1%
RAD51D 1% 0.6% 0.6%
RAD50 0.2% 0.2%
ATM/ATR 0.4% 0.6% 0.5%
FANC 0.7%
BARD1 0.5% 0% 0.2% 0.5%
BRIP1 1% 0.4% 1.4% 2.5%
CHEK1 0.25% 0.2%
CHEK2 0.7% 0.6% 0.6%
FAM175A 0.5% 0.2% 0.2%
NBN 0.25% 0.4% 0.5% 0.5%
PALB2 0.5% 1.1% 0.6% 0.5%
MRE11A 0.4% 0.1%
MMR 0.6% 0.5%
TP53 0% 0.3%
FANC: Fanconi anemia complementation group; MMR: mismatch repair genes.
Table 3 - Frequency of somatic gene changes (mutation,
deletion or amplification) in ovarian carcinoma.
(N) TCGA
(14)
(316)
Pennington
et al. (19)
(390)
Cunningham
et al. (13)
(279)
Hahnen
et al. (52)
(431)
Aghajanian
et al. (20)
(260)
BRCA1 3.2% 4.9% 2% 3% 4.4%
BRCA2 2.9% 1.5% 1.4% 1.4% 2.2%
EMSY 8%
PTEN 7% 4.4%
RAD51C 0.3% 0.3%
RAD51D 0.2%
RAD50 0.6%
ATM/ATR 2% 0.8% 0.2% 2.2%
FANC 5% 0.2% 0.3%
BARD1 0.6%
BRIP1 0.5% 0.6%
CHEK1 0% 0.3%
CHEK2 0.3% 0.8% 0.3%
FAM175A
NBN 0.3%
PALB2 0.2% 0.3%
MRE11A 0.3%
MMR 0.4%
TP53
FANC: Fanconi anemia complementation group; MMR: mismatch repair
genes.
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while no response was observed in patients without BRCA
mutations.
A benefit of olaparib in patients with BRCA mutations
was also suggested in the phase II study 19 trial (27). This
trial evaluated olaparib maintenance in platinum-sensitive
patients with or without BRCA mutations and showed
improved progression free survival (PFS) in comparison to
that of patients receiving the placebo (8.4 months versus
4.8 months; hazard ratio, 0.35; 95% CI, 0.25-0.49; po0.001).
However, the benefit was greater in patients with BRCA
mutations (11.2 vs 4.3 months; hazard ratio, 0.18; 95% CI,
0.10-0.31; po0.0001) than in BRCA wild-type patients (7.4 vs
5.5 months; hazard ratio, 0.54; 95% CI, 0.34-0.85, p=0.0075).
Furthermore, in a post hoc analysis, when excluding patients
who crossed over to olaparib after progression, an improved
overall survival with olaparib was observed in the group with
BRCA mutations (hazard ratio, 0.52; 95% CI, 0.28-0.97) (28).
Another single-arm phase II study evaluated olaparib in
patients with germline BRCA mutations previously treated
with at least three lines of chemotherapy (5). The results were
impressive in this heavily pretreated population, with a
response rate of 31.1% in ovarian cancer patients, a median
PFS of 7 months and a median overall survival of 16.6 months.
These results lead to the Food and Drug Administration
(FDA) approval of olaparib for this scenario.
Recently, results of the phase III SOLO 2 trial were pub-
lished, showing that patients with BRCA mutations that had
previously received at least two lines of chemotherapy benef-
ited from olaparib maintenance after response to platinum-
based chemotherapy for the treatment of relapsed ovarian
cancer. The risk of progression was reduced by 70%, with an
absolute gain in PFS of 13.6 months (median PFS of 19.1 months
with olaparib versus 5.5 months with the placebo; hazard ratio,
0.3; 95% CI, 0.22-0.41; po0.0001).
Another PARP inhibitor, niraparib, also demonstrated
efficacy in patients with ovarian cancer with or without
BRCA mutations. The NOVA trial showed that as a main-
tenance therapeutic, niraparib improves the PFS of platinum-
sensitive patients (4). In that trial, the presence of BRCA
mutations and HRD determined using the Myriad Genetics
HRD score were investigated. While a benefit was observed
in all subgroups, the PFS of patients with BRCA mutations
(21.0 months vs 5.5 months; hazard ratio, 0.27; 95% CI, 0.17-
0.41) and BRCA wild-type/HRD-high (20.9 months vs
11.0 months; hazard ratio, 0.27; 95% CI, 0.08-0.90) was increa-
sed to a greater extent than that of BRCAwild-type/HRD-low
patients (6.9 months vs 3.8 months; hazard ratio, 0.58; 95% CI,
0.36-0.92).
The phase II Ariel 2 trial also confirmed the benefit of
PARP inhibitors to patients with HRD in general (9). In this
trial, rucaparib was used in advanced ovarian cancer patients
previously treated with two or more lines of chemotherapy
(regardless of their platinum sensitivity). HRD was assessed
by evaluating both BRCA germline mutations and LOH. Once
again, the response rate (RR) and PFS were higher in BRCA
germline mutation carrier patients (RR, 69%; PFS, 12.8 months;
hazard ratio, 0.27; 95% CI, 0.16-0.44; po0.0001) and BRCA
wild-type LOH-high patients (RR, 39%; PFS, 5.7 months;
hazard ratio, 0.62; 95% CI, 0.42-0.9; p=0.011) than in BRCA
wild-type/LOH-low patients (RR, 11%; PFS, 5.1 months).
The phase III Ariel 3 trial showed that rucaparib also
improved the PFS as a maintenance therapeutic in ovarian
cancer patients in comparison with the placebo after treat-
ment with at least two lines of platinum-based therapy with
response to the last treatment (29). PFS was improved in the
three nested cohorts: patients with BRCA mutations (median
PFS, 16.6 months vs 5.4 months; hazard ratio, 0.23; 95% CI,
0.16-0.34; po0.0001), patients with HRD (including BRCA-
mut and BRCAwt/high-LOH carcinomas) (median PFS, 13.6
months vs 5.4 months; hazard ratio, 0.32; 95% CI, 0.24-0.42;
po0.0001) and the intention-to-treat population (median PFS,
10.8 months versus 5.4 months; hazard ratio, 0.36; 95% CI,
0.30-0.45; po0.0001). In a non-nested subgroup analysis,
the absolute gain in median PFS was 4.3 months for BRCA
wild-type patients with LOH-high (9.7 months vs 4 months;
hazard ratio, 0.44; po0.001) and 1.3 months for those with
LOH-low (6.7 months vs 5.4 months; hazard ratio, 0.58;
p=0.0049).
In conclusion, the trials show that the benefits of PARP
inhibitors extend beyond BRCA 1/2 mutations. Patients with
HRDs of different etiologies might benefit from these drugs,
increasing the number of patients who might benefit from
these treatments. Some studies also showed a statistically
significant benefit for the PFS of patients with HR profi-
ciency, but the clinical relevance of the gain in this scenario
was smaller.
Perspectives
Studies are ongoing to investigate whether combinations
of PARP inhibitors and other drugs might improve their
efficacy in patients with or without HRD.
As mentioned previously, when HRD is present, the use
of PARP inhibitors induces synthetic lethality. In patients
without HRD, using drugs in combination might exert a
similar effect, defined as ‘contextual’ synthetic lethality (30).
Hypoxic conditions, for example, appear to downregulate
DNA repair and generate genomic instability (30,31). Thus,
the combination of antiangiogenic agents and PARP inhibi-
tors represents a potential mechanism underlying contextual
synthetic lethality. In a phase II trial, olaparib was combined
with the VEGFR inhibitor cediranib, and an improved in PFS
was observed (17.7 months versus 9 months with olaparib
alone; hazard ratio, 0.42; 95% CI, 0.23-0.76; p=0.005) (32).
Upon subgroup analysis, patients with HR proficiency bene-
fited the most from the synergism of the two drugs (PFS of
16.5 vs 5.7 months with olaparib alone; hazard ratio, 0.32;
p=0.008). Patients with germline BRCA mutations had a good
response to olaparib alone, as expected, and an improvement
trend in PFS was observed with the combination (PFS of
19.5 months vs 16.5 months with olaparib alone).
For patients with HRD who develop resistance to PARP
inhibitors, the association of VEGFR and PARP inhibitors
represents a potential strategy to overcome resistance. Thus,
a study evaluating the combination of cediranib and olaparib
in advanced ovarian cancer after progression on a PARP
inhibitor is currently ongoing (ClinicalTrials.gov, NCT02681237).
PI3K inhibitors are also associated with decreased HR repair.
Preclinical studies showed that PI3K inhibitors decrease the
expression of RAD51 and are synergistic with olaparib (33,34).
In addition to PI3K and VEGFR inhibitors, other agents
that decrease DNA repair with the potential to function syn-
ergistically with PARP inhibitors include inhibitors of CHK1,
ATR, Wee, BET (35-39). Preclinical studies have shown pro-
mising results when these agents are used in combination
with PARP inhibitors.
Furthermore, cytotoxic chemotherapy might potentiate the
effect of PARP inhibitors via the association of DNA damage
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and inhibition of DNA repair. In a phase I trial, the com-
bination of olaparib and carboplatin yielded an overall RR of
44% in patients with germline BRCA mutations and ovarian
cancer (40).
Another important point to consider is that adaptive
resistance develops over time when a drug is used as mono-
therapy, and combination therapy could help avoid or retard
the development of adaptive resistance.
Different mechanisms are implicated in the resistance to
PARP inhibitors. In BRCA-mutated tumors, the development
of secondary reversion mutations that restore BRCA func-
tion and HR activity appears to be an important mechanism
underlying resistance (41,42).
Resistance might also occur upon the activation of signal-
ing cascades implicated in tumorigenesis, such as the PI3K/
AKT and RAS/MAPK pathways (34,43).
As mentioned previously, PI3K inhibitors improve the
activity of olaparib (33,34), and PARP and MEK inhibitors
also function synergistically when used in combination both
in vitro and in vivo (43). RAS mutant lines, for example, are
resistant to PARP inhibitors but sensitive to the combination
of PARP and MEK inhibitors (43). A study on using the MEK
inhibitor selumetinib and olaparib in combination to treat
RAS-activated tumors is currently ongoing (ClinicalTrials.
gov, NCT03162627).
Importantly, the combinations described above are poten-
tial treatment strategies for improving the efficacy of PARP
inhibitors in patients with HR proficiency and patients with
HRD that acquire resistance to PARP inhibitors.
The increase in drug efflux by P-glycoproteins (P-gp) also
leads to PARP resistance, which was reversed by the coad-
ministration of the P-gp inhibitor tariquidar in a preclinical
study (44). Moreover, differences exist between PARP inhi-
bitors, and while olaparib appears to be a substrate of P-gp,
veliparib does not (45).
Alterations in PARP expression might also play a role in
PARP resistance, and these effects may vary among different
PARP inhibitors. While olaparib and veliparib specifically
inhibit PARP1 and PARP2, niraparib, rucaparib and talazo-
parib inhibit a broader range of PARP enzymes (46). Thus,
the possibility exist that after progression on one PARP
inhibitor, another could still be active. However, this hypo-
thesis needs to be investigated further.
Finally, the combination of PARP inhibitors with immu-
notherapy is also being studied (47). BRCA 1/2-mutated
HGSOC exhibits a higher mutational load, more tumor-
specific antigens, more tumor-infiltrating lymphocytes and
higher PD-1 and PD-L1 expression in tumor-associated
immune cells than HR-proficient HGOSC (48). These find-
ings suggest that BRCA 1/2-mutated HGSOC may be more
sensitive to PD1/PL-L1 inhibitors. Furthermore, the inhibi-
tion of DNA repair pathways propagating DNA damage
and neoantigen formation could improve the activity of
immunotherapy.
’ CONCLUSIONS
The prevalence of HRD is high in ovarian cancer. Further
understanding HRD and recognizing the existence of the
BRCAness phenotype could lead to a broader group of
patients benefiting from PARP inhibitors.
The best strategy to evaluate HRD still needs to be defined.
Germline or somatic mutations can be assessed using NGS,
while genomic instability can be determined by evaluating
the LOH, telomeric allelic imbalance, and large-scale transi-
tions. Each of these options has advantages and disadvan-
tages, and they should be used in a complementary manner.
Future studies on PARP inhibitors should continue to vali-
date the clinical utility of these strategies to assess HRD.
Finally, the combination of PARP inhibitors with other
drugs is promising. Currently, contextual synthetic lethality
and strategies to overcome adaptive resistance have been
studied using a combination of PARP inhibitors and other
drugs, such as cytotoxic chemotherapy, angiogenesis inhibi-
tors, MEK inhibitors and immunotherapy. These combina-
tions might improve the efficacy of PARP inhibitors even
in patients without HRD, extending the benefit of these
drugs even further. We eagerly await further results from
these studies.
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